DOCSLIB.ORG

Bronchitis - Chronic in Acute Exacerbation (1 of 11)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bronchitis - Chronic in Acute Exacerbation (1 of 11) Bronchitis - Chronic in Acute Exacerbation (1 of 11) 1 Patient w/ chronic bronchitis presents w/ increasing symptoms 2 DIAGNOSIS Is acute exacerbation of No ALTERNATIVE chronic bronchitis DIAGNOSIS (AECB) con rmed? Yes 3 EVALUATION Mild Does patient have mild, Severe moderate or severe exacerbation? Moderate A Non-pharmacological A Non-pharmacological A Non-pharmacological therapy therapy therapy • Lifestyle modi cation • Lifestyle modi cation • Lifestyle modi cation • Patient education MIMS• Patient education • Patient education B Pharmacological therapy • Supportive therapy • Supportive therapy • Bronchodilators (Inhaled) - O, if required - O, if required - Noninvasive - Noninvasive positive-pressure positive-pressure ventilation, if required ventilation, if required B Pharmacological therapy B Pharmacological therapy • Bronchodilators (Inhaled) • Bronchodilators (Inhaled) • Corticosteroids (Systemic) • Corticosteroids (Systemic) © • Empiric antibiotics • Empiric antibiotics Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B1 © MIMS 2019 Bronchitis - Chronic in Acute Exacerbation (2 of 11) 1 ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB) • Chronic bronchitis: Clinical diagnosis of sputum expectoration on most days during at least 3 consecutive months for ≥2 consecutive years • Symptoms of exacerbation are increase in dyspnea, sputum volume & sputum purulence over baseline 2 DIAGNOSIS BRONCHITIS - CHRONIC • Diagnosis is typically based on clinical presentation Clinical Presentation History • History of chronic bronchitis w/ acute onset of symptoms which include the following: - Major criteria: Increase in sputum volume, increase in sputum purulence & increased dyspnea - Minor criteria: Wheezing, sore throat, cough & symptoms of a common cold (eg nasal congestion/discharge, fever, 20% increase in respiratory rate or heart rate above baseline) • Exacerbation is usually considered if at least 2 major criteria are present or depending on the de nition used, the presence of at least 1 major & 1 minor symptom for at least 2 consecutive days Physical Exam • ere are no characteristic physical ndings in acute exacerbation of chronic bronchitis (AECB) but the following physical ndings may be found: - Increased respiratory rate - Increased wheezing - Di use crackles without localization, may be present • Consider the possibility of pneumonia if there is evidence of consolidation (eg localized crackles, bronchial breath sounds, dullness on percussion) • Elevated body temperature usually suggests viral infection or underlying pneumonia as a cause of an AECB Risk Factors for Exacerbations • Tracheobronchial infections (eg in uenza, streptococcal infection) • Environmental exposures (eg air pollution) • Noncompliance w/ inhaled bronchodilator therapy or pulmonary rehabilitation program Further Investigations Chest X-Ray • Chest X-ray is not helpful in making the diagnosis of AECB - May consider if needed to exclude other diseases that may complicate the condition eg pneumonia or congestive heart failure (CHF) Gram Stain/Culture • Sputum Gram stain & culture should be limited to patients w/ severe chronic obstructive pulmonary disease (COPD), frequent exacerbations or bronchiectasis in whom the presence of more virulent &/or resistant bacteria is more likely - Gram stain/culture has a limited role in the investigation of AECB since 30-50% of chronic bronchitis su erers are colonized w/ non-encapsulated Haemophilus infl uenzae, Streptococcus pneumoniae & Moraxella catarrhalis Pulmonary Function • Pre-morbid forced expiratory volume in 1 second (FEV) values are a predictor of adverse outcomes during an AECB but it is not necessary to performMIMS FEV during the actual exacerbation • ere is no clear correlation between transient falls in lung function & the severity of exacerbation - Objective measurements of pulmonary function should be done after the recovery of patients w/ AECB O2 Saturation, Arterial Blood Gas • Measurement© of O saturation (+/- blood gases) is recommended in moderate to severe cases to guide therapy B2 © MIMS 2019 Bronchitis - Chronic in Acute Exacerbation (3 of 11) 3 EVALUATION Severe Exacerbation • Severe exacerbation is considered when all 3 major criteria are present: - Increase in sputum volume, increase in sputum purulence & increased dyspnea • Patients w/ severe exacerbations are more likely to bene t from antibiotic treatment Moderate Exacerbation • Moderate exacerbation is considered when 2 of the 3 major criteria are present BRONCHITIS - CHRONIC • ese patients may bene t from antibiotic treatment Mild Exacerbation • Mild exacerbation is considered when 1 of the major criteria is present along w/ at least 1 minor criteria • Studies have shown that antibiotics are generally no more e ective than placebo in these patients GOALS OF THERAPY • Rapid resolution of symptoms • Prevent transient loss of pulmonary function • Reduce the bacterial burden in the lower respiratory tract • Prevent relapse or lengthen the time between exacerbations • Re-evaluation of the disease to reduce the risk of future exacerbations A NON-PHARMACOLOGICAL THERAPY Lifestyle Modi cation Smoking Cessation • A discussion of smoking behavior & the setting of a speci c cessation date should be part of every physician-pa- tient encounter • Patients presenting w/ AECB should be encouraged to stop smoking since it is the most e ective way to reduce the risk of future morbidity from chronic bronchitis • It can lead to dramatic symptomatic bene ts for patients w/ chronic bronchitis eg stopping cough in 94-100%; when coughing stops, it can occur in as quickly as 4 weeks in 54% of patients Reduction/Elimination of Irritants • Reduction or elimination of any source of irritants that may worsen lower airway in ammation - Includes environmental pollutants (eg dust, pollutants & second-hand smoke) & occupational irritants Patient Education • Educate patient about the nature of the chronic bronchitis (the progressive nature & its potential impact on future lifestyle & function) • Review w/ the patient the signs of onset of infection (eg increased purulence, viscosity or volume of secretions) that should be treated early • Discuss measures that may limit the spread of viral infections (eg hand washing) • Encourage patients to exercise regularly - Although not accompanied by measurable improvement in lung function, it will increase exercise tolerance & improve the patient’s sense of well-being Supportive erapy MIMS Hydration • Maintain adequate hydration to prevent excessive mucus viscosity Nutritional Programs • ere are no direct or measurable e ects on lung function in treating malnutrition but subjective relief & objective improvement in strength & exercise performance do occur - Dietary supplementation should be considered if patient is malnourished (body weight <85% of ideal) or experiencing early satiety • Advise patient© to obtain nutritional counseling to reduce weight if obese B3 © MIMS 2019 Bronchitis - Chronic in Acute Exacerbation (4 of 11) A NON-PHARMACOLOGICAL THERAPY (CONT'D) Supportive erapy (Cont'd) Oxygen erapy • Cornerstone of COPD exacerbation treatment • Low- ow O should be administered if hypoxemia is present • Excess use of O should be avoided as this may lead to progressive hypercapnia, either by decreasing hypoxic ventilatory drive or by worsening ventilation-perfusion mismatching within the lungs BRONCHITIS - CHRONIC • Once O therapy is initiated, arterial blood gas should be monitored 30-60 minutes later to ensure satisfactory oxygenation without acidosis or CO retention • Goal of supplemental O therapy should be arterial oxygen partial pressure at or just above 60 mmHg Noninvasive Positive Pressure Ventilation • Frequently used for inpatient management of AECB patients who are signi cantly hypoxemic or w/ a serum pH <7.3 • Improves ventilation & lower pCO levels & may be a means of avoiding intubation • Decreases hospital or intensive care unit length of stay & morbidity B PHARMACOLOGICAL THERAPY Bronchodilators • Bronchodilators should be used for the treatment of dyspnea accompanying an exacerbation Short-Acting Anticholinergics (Inhaled) • Eg Ipratropium bromide • E ects: An e ective bronchodilator w/ a slower onset of action & a slightly longer duration of action compared to short-acting beta-agonists, but no appreciable di erence between the two in terms of e ects on pulmonary function - Decreased cough frequency & sputum volume have been noted in patients using Ipratropium - Side e ects may be fewer compared to Salbutamol • Available in metered-dose inhalers (MDIs) & nebulizer solution - ere is no signi cant di erence in pulmonary function outcomes between delivery system, but in most situations, MDIs w/ an appropriate spacer would be preferred Short-Acting Beta-Agonists (Inhaled) • Short-acting inhaled beta-agonists are usually the preferred bronchodilators - Addition of anticholinergics is recommended should there be no prompt response w/ inhaled beta2-agonists • Produce e ective bronchodilatation w/ a faster onset of action than anticholinergics, but no appreciable di erence between the two in terms of e ects on pulmonary function • Available in MDI & nebulizer solution • e role of long-acting beta-agonists has not been studied in AECB therefore are not recommended for treatment of the condition at the present time Methylxanthines • e use of methylxanthines in AECB is not indicated - e addition of Aminophylline to
Load more

Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors
    저작자표시-비영리-변경금지 2.0 대한민국 이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다. 다음과 같은 조건을 따라야 합니다: 저작자표시. 귀하는 원저작자를 표시하여야 합니다. 비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건 을 명확하게 나타내어야 합니다. l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다. 저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다. Disclaimer 약학 석사학위 논문 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 2017년 8월 서울대학교 대학원 약학과 사회약학전공 권 익 태 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 지도교수 홍 송 희 이 논문을 권익태 석사학위논문으로 제출함 2017년 4월 서울대학교 대학원 약학과 사회약학전공 권 익 태 권익태의 석사학위논문을 인준함 2017년 6월 위 원 장 (인) 부 위 원 장 (인) 위 원 (인) Abstract Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors Ik Tae Kwon Department of Social Pharmacy College of Pharmacy, Seoul National University Background Angiotensin-converting enzyme inhibitors (ACEI) can induce a dry cough, more frequently among Asians. If healthcare professionals fail to detect coughs induced by an ACEI, patients are at risk of getting antitussives inappropriately instead of discontinuing ACEI. The purpose of this study was to examine how the initiation of ACEI affects the likelihood of antitussive uses compared with the initiation of Angiotensin Receptor Blocker (ARB) and to determine the effect of the antitussive use on the duration and adherence of therapy in a Korean population.
    [Show full text]
  • Elif Fatma Sen BW.Indd
    Use and Safety of Respiratory Medicines in Children E. F. Şen EEliflif FFatmaatma SSenen BBW.inddW.indd 1 003-01-113-01-11 115:175:17 The work presented in this thesis was conducted at the Department of Medical Informatics of the Erasmus University Medical Center, Rotterdam. The research reported in thesis was funded by the European Community’s 6th Framework Programme. Project number LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young. The contributions of the participating primary care physicians in the IPCI, Pedianet and IMS-DA project are greatly acknowledged. Financial support for printing this thesis was kindly provided by the department of Medical Informatics – Integrated Primary Care Information (IPCI) project of the Erasmus University Medi- cal Center; and by the J.E. Jurriaanse Stichting in Rotterdam. Cover: Optima Grafi sche Communicatie Printed by: Optima Grafi sche Communicatie Elif Fatma Şen Use and Safety of Respiratory medicines in Children ISBN: 978-94-6169-003-6 © E.F. Şen, Rotterdam, the Netherlands, 2011. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the holder of the copyright. EEliflif FFatmaatma SSenen BBW.inddW.indd 2 003-01-113-01-11 115:175:17 Use and Safety of Respiratory Medicines in Children Het gebruik en de bijwerkingen van respiratoire medicijnen in kinderen Proefschrift Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr.
    [Show full text]
  • Mucoactive Agents for Airway Mucus Hypersecretory Diseases
    Mucoactive Agents for Airway Mucus Hypersecretory Diseases Duncan F Rogers PhD FIBiol Introduction Sputum Profile of Airway Inflammation and Mucus Hypersecretory Phenotype in Asthma, COPD, and CF Which Aspect of Airway Mucus Hypersecretion to Target? Theoretical Requirements for Effective Therapy of Airway Mucus Hypersecretion Current Recommendations for Clinical Use of Mucolytic Drugs Mucoactive Drugs N-Acetylcysteine: How Does it Work? Does it Work? Dornase Alfa Hypertonic Saline Surfactant Analysis Summary Airway mucus hypersecretion is a feature of a number of severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). However, each disease has a different airway inflammatory response, with consequent, and presumably linked, mucus hypersecretory phenotype. Thus, it is possible that optimal treatment of the mucus hyper- secretory element of each disease should be disease-specific. Nevertheless, mucoactive drugs are a longstanding and popular therapeutic option, and numerous compounds (eg, N-acetylcysteine, erdosteine, and ambroxol) are available for clinical use worldwide. However, rational recommen- dation of these drugs in guidelines for management of asthma, COPD, or CF has been hampered by lack of information from well-designed clinical trials. In addition, the mechanism of action of most of these drugs is unknown. Consequently, although it is possible to categorize them according to putative mechanisms of action, as expectorants (aid and/or induce cough), mucolytics (thin
    [Show full text]
  • United States Patent (10) Patent No.: US 9,724,340 B2 Liang Et Al
    USOO9724340B2 (12) United States Patent (10) Patent No.: US 9,724,340 B2 Liang et al. (45) Date of Patent: Aug. 8, 2017 (54) ANTITUSSIVE COMPOSITIONS AND 5,952,339 A 9, 1999 Bencherif METHODS 5,969,144 A 10, 1999 London 6.432,975 B1 8, 2002 Schmitt 6,734,215 B2 5/2004 Shytle (71) Applicant: Attenua, Inc., New York, NY (US) 6,953,855 B2 10/2005 MaZurov et al. 7,115,629 B2 10/2006 Farrerons (72) Inventors: Jing Liang, New York, NY (US); Peter 7.425,561 B2 9/2008 MaZurov et al. Dicpinigaitis, Armonk, NY (US); 7,754,189 B2 7/2010 MaZurov et al. Brendan Canning, Baltimore, MD 7,767,193 B2 8, 2010 MaZurov et al. s 7.981906 B2 7, 2011 Dull et al. (US); Robert Devita, Westfield, NJ 8,084,462 B2 12/2011 MaZurov et al. (US) 8,119,659 B2 2/2012 Dullet al. 8,124,618 B2 2/2012 Mazurov et al. (73) Assignee: Attenua, Inc., New York, NY (US) 8,124,619 B2 2/2012 MaZurov et al. 8,143,272 B2 3/2012 MaZurov et al. (*) Notice: Subject to any disclaimer, the term of this 8,476,2968, 158,649 B2 4/20127/2013 MazurovBencherif et et al. al. patent is extended or adjusted under 35 8,541,446 B2 9/2013 Bencherif et al. U.S.C. 154(b) by 0 days. 8,541,447 B2 9/2013 MaZurov et al. 8,846,715 B2 9/2014 Bencherif et al. (21) Appl. No.: 15/208,266 8,901,151 B2 12/2014 Bencherif et al.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Diccionario Del Sistema De Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS
    DIRECCION GENERAL DE MEDICAMENTOS, INSUMOS Y DROGAS - DIGEMID EQUIPO DE ASESORIA - AREA DE CATALOGACION Diccionario del Sistema de Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS CODIGO DESCRIPCION ATC EN CASTELLANO DESCRIPCION ATC EN INGLES FUENTE A TRACTO ALIMENTARIO Y METABOLISMO ALIMENTARY TRACT AND METABOLISM ATC OMS A01 PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01A PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01AA Agentes para la profilaxis de las caries Caries prophylactic agents ATC OMS A01AA01 Fluoruro de sodio Sodium fluoride ATC OMS A01AA02 Monofluorfosfato de sodio Sodium monofluorophosphate ATC OMS A01AA03 Olaflur Olaflur ATC OMS A01AA04 Fluoruro de estaño Stannous fluoride ATC OMS A01AA30 Combinaciones Combinations ATC OMS A01AA51 Fluoruro de sodio, combinaciones Sodium fluoride, combinations ATC OMS A01AB Antiinfecciosos y antisépticos para el tratamiento oral local Antiinfectives and antiseptics for local oral treatment ATC OMS A01AB02 Peróxido de hidrógeno Hydrogen peroxide ATC OMS A01AB03 Clorhexidina Chlorhexidine ATC OMS A01AB04 Amfotericina B Amphotericin B ATC OMS A01AB05 Polinoxilina Polynoxylin ATC OMS A01AB06 Domifeno Domiphen ATC OMS A01AB07 Oxiquinolina Oxyquinoline ATC OMS A01AB08 Neomicina Neomycin ATC OMS A01AB09 Miconazol Miconazole ATC OMS A01AB10 Natamicina Natamycin ATC OMS A01AB11 Varios Various ATC OMS A01AB12 Hexetidina Hexetidine ATC OMS A01AB13 Tetraciclina Tetracycline ATC OMS A01AB14 Cloruro de benzoxonio
    [Show full text]
  • Electronic Supplementary Material
    Supplementary material Thorax Electronic Supplementary Material Contents: MEDLINE search strategy: ........................................................................................................ 1 Number of search results according to data source: .................................................................. 4 Inclusion/Exclusion criteria of eligible trials: ............................................................................ 5 List of excluded studies after full text review: ......................................................................... 14 Reporting of adverse events and development of other pathologies: ...................................... 19 Deviations between this review and protocol: ......................................................................... 20 Funnel Plots: ............................................................................................................................ 20 Explanation for observed Risk of Bias differences for included trials between this review and Tarrant 2019 review: ................................................................................................................ 24 MEDLINE search strategy: Search was adapted appropriately for other databases. Condition: 1. Acute hypoxic respiratory failure 2. Acute hypoxemic respiratory failure 3. Acute hypoxaemic respiratory failure 4. Acute hypercapnic respiratory failure 5. AHRF 6. Respiratory Distress Syndrome, Adult/ 7. Acute respiratory failure 8. ARF 9. Severe hypoxic respiratory failure 10. Severe
    [Show full text]
  • Bronchitis - Uncomplicated Acute (1 of 8)
    Bronchitis - Uncomplicated Acute (1 of 8) 1 Patient presents w/ symptoms of lower resp tract infection (LRTI) 2 EVALUATION Yes ALTERNATIVE Comorbid condition DIAGNOSIS present or is patient >60 years? No 3 DIAGNOSIS No ALTERNATIVE Uncomplicated acute DIAGNOSIS bronchitis Yes Is No pertussis Yes suspected? A Pharmacological therapy A Pharmacological therapy Symptomatic therapy Oral Antibiotic • Analgesics (non-opioid) & Any one of the following: Antipyretics • Co-trimoxazole • Bronchodilator: Beta2-agonist • Macrolide (inhaled) MIMS • Cough & Cold Preparations B Patient education C Follow-up ©• Not usually necessary Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B26 © MIMS 2019 Bronchitis - Uncomplicated Acute (2 of 8) 1 BRONCHITIS - UNCOMPLICATED ACUTE Signs & Symptoms of Lower Respiratory Tract Infection: • Cough &/or increase in sputum production • Breathlessness/wheeze • Chest pain/aches • Sweats &/or sore throat • BRONCHITIS - ACUTE Increase in temperature Uncomplicated Acute Bronchitis • A self-limiting acute respiratory tract infection characterized by the sudden onset of cough, w/ or without sputum production, in an otherwise healthy individual - Diagnosis is based on clinical fi ndings Pathogenesis • An infl ammatory response to infections of the bronchial epithelium of the large airways of the lungs - Begins w/ mucosal injury, epithelial cell damage & release of proinfl ammatory mediators - Transient airfl ow obstruction & bronchial hyperresponsiveness
    [Show full text]
  • Diclofenac Inhibits Phorbol Ester-Induced Gene Expression
    Original Article Biomol Ther 28(5), 431-436 (2020) Diclofenac Inhibits Phorbol Ester-Induced Gene Expression and Production of MUC5AC Mucin via Affecting Degradation of IkBα and Translocation of NF-kB p65 in NCI-H292 Cells Fengri Jin1,†, Xin Li1,†, Hyun Jae Lee2,* and Choong Jae Lee1,* 1Department of Pharmacology, School of Medicine, Chungnam National University, Daejeon 35015, 2Smith Liberal Arts College and Department of Addiction Science, Graduate School, Sahmyook University, Seoul 01795, Republic of Korea Abstract In this study, diclofenac, a non-steroidal anti-inflammatory drug, was investigated for its potential effect on the gene expression and production of airway MUC5AC mucin. The human respiratory epithelial NCI-H292 cells were pretreated with diclofenac for 30 min and stimulated with phorbol 12-myristate 13-acetate (PMA), for the following 24 h. The effect of diclofenac on PMA-induced nuclear factor kappa B (NF-kB) signaling pathway was also investigated. Diclofenac suppressed the production and gene expres- sion of MUC5AC mucins, induced by PMA through the inhibition of degradation of inhibitory kappa Bα (IkBα) and NF-kB p65 nuclear translocation. These results suggest diclofenac regulates the gene expression and production of mucin through regulation of NF-kB signaling pathway, in human airway epithelial cells. Key Words: MUC5AC, Pulmonary mucin, Diclofenac INTRODUCTION for regulating the pathological hypersecretion of airway mu- cus. Although glucocorticoids have been reported to suppress Pulmonary mucus containing mucins (mucous glycopro- the hypersecretion and/or hyperproduction of airway mucins, teins), the major macromolecular component that gives mucus they showed a multitude of adverse effects in the course of the viscoelasticity, protects the respiratory system from inhaled pharmacotherapy (Sprenger et al., 2011).
    [Show full text]
  • Wo 2007/016677 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 8 February 2007 (08.02.2007) PCT WO 2007/016677 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/5377 (2006.01) kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, (21) International Application Number: CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, PCT/US2006/030287 GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, (22) International Filing Date: 2 August 2006 (02.08.2006) LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MZ, NA, (25) Filing Language: English NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, (26) Publication Language: English UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 60/704,426 2 August 2005 (02.08.2005) US kind of regional protection available): ARIPO (BW, GH, 60/741,455 2 December 2005 (02.12.2005) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicant (for all designated States except US): NI- European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, TROMED, INC.
    [Show full text]
  • European Respiratory Society Annual Congress 2013 Abstract Number: 2089 Publication Number: P1208 Abstract Group: 7.4
    European Respiratory Society Annual Congress 2013 Abstract Number: 2089 Publication Number: P1208 Abstract Group: 7.4. Paediatric Respiratory Infection and Immunology Keyword 1: Children Keyword 2: Cough Keyword 3: Pharmacology Title: Antibiotic or symptomatic therapy in URTI-related pediatric acute cough? Dr. Alessandro 18512 Zanasi [email protected] MD 1, Dr. Luigi 18513 Lanata [email protected] MD 2, Dr. Francesco 18514 De Blasio [email protected] MD 3, Dr. Federico 18515 Saibene [email protected] MD 2, Dr. Giovanni 18516 Fontana [email protected] MD 5, Dr. Rossella 18539 Balsamo [email protected] MD 2 and Dr. Peter 18517 Dicpinigaitis [email protected] MD 4. 1 Pneumology Unit, University of Bologna, S.Orsola Malpighi Hospital, Bologna, Italy ; 2 Medical Department, Dompé SPA, Milan, Italy ; 3 Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center, Private Hospital, Naples, Italy ; 4 Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, United States and 5 Medical Department, University of Florence, Careggi Hospital, Florence, Italy . Body: Acute cough is a widespread symptom in children, the disproportionate use of antibiotic prescription increases parental satisfaction, although URTI are generally self-limiting. We analyzed treatment effect of antibiotics and symptomatic drugs (antitussives and mucolitics) in two trials on URTI-related cough. The first retrospective study involved 59 children with acute moist cough, treated with antibiotics or inhaled mucoactive drugs. Cough was measured, by means of a verbal category descriptive (VCD) score. The second prospective study included 305 children with acute cough. Severity, frequency and type of cough were assessed after 6 days of treatment using a standardized questionnaire.
    [Show full text]